Search Your Queries Related To Trilegal
Pattern background design

Deal: Trilegal advised Mallinckrodt in a strategic merger with Endo, valued at USD 6.7 billion

18 Mar 2025

Trilegal advised Mallinckrodt in a strategic merger with Endo, valued at USD 6.7 billion

Trilegal advised Mallinckrodt as the Indian legal advisor, on its merger with Endo, Inc., in a cash-and-stock transaction valued at $6.7 billion. Pursuant to the deal, Endo shareholders will retain a 49.9% stake in the combined company, and Mallinckrodt shareholders will hold a 50.1% majority stake. Mallinckrodt will serve as the holding company for the newly merged entity, with Endo and its Indian entities – Par Formulations Private Limited, Par Active Technologies Private Limited, and Par Biosciences Private Limited becoming subsidiaries.

The transaction will be financed through a combination of cash on hand and $900 million in committed financing from Goldman Sachs & Co. LLC, alongside the refinancing of Mallinckrodt’s existing senior secured debt. Completion of the transaction is subject to shareholder and regulatory approvals, including antitrust clearance in key jurisdictions and Foreign Direct Investment (FDI) approval in India. The combined company is expected to be listed on the New York Stock Exchange (NYSE).

As part of its role as legal counsel, Trilegal conducted comprehensive corporate due diligence on Endo’s Indian entities, reviewed the Merger Agreement from an Indian law perspective, and assessed the merger under Indian merger control regulations.

The merger underscores key trends in pharmaceutical M&A, including strategic consolidation, leveraged financing, and regulatory scrutiny. The deal’s financing structure – combining cash on hand, $900 million in committed financing from Goldman Sachs & Co. LLC, and debt refinancing reflects the growing emphasis on capital structure optimization. The structured ownership split ensures balanced shareholder representation. The NYSE listing post completion underscores the potential for growth in the pharmaceutical business and role of public markets in large-scale pharma M&A deals.

The Trilegal Corporate Team advising on the mandate was led by Partner: Delano Furtado, and supported by Counsel: Saumya Kakar, Senior Associate: Neil Lopez; and Associates: Ridhi Shetty, Pranika Correa, Rhea Almeida, Anoushka Gahilot, and Punit Sanwal.

The Trilegal Competition Team advising on the mandate was led by Partner: Aparna Mehra; supported by Senior Associate: Ishaan Chakrabarti; and Associates: Karan Arora and Ashlesha Singhal.

Media link:

https://www.wsj.com/business/deals/mallinckrodt-endo-merger-to-create-diversified-pharmaceuticals-firm-9467a305

About Trilegal

Trilegal is one of India’s leading law firms, with expertise across the full spectrum of corporate legal services. Trilegal has offices in four key cities of India.

Trilegal has been recognised as M&A Firm of the Year by IFLR Asia-Pacific 2024Best Overall Law Firms by India Business Law Journal (IBLJ) 2024Innovative Lawyers Asia-Pacific by Financial Times (FT) 2024Law Firm of the Year by Deal Volume by VCCircle Awards 2024; India Deal Firm of the Year by Asian Legal Business (ALB) India Law Awards 2023; Best Law Firms to Work by Vahura 2022Firm of the year for Client Service Excellence by Asia Law Awards 2021.

For more information, please get in touch with Prakruti Jani | Mob: +91-9867868976 | BD@trilegal.com

Trending News

Let's connect

Disclaimer

Under the rules of the Bar Council of India, Trilegal is prohibited from soliciting work or advertising in any form or manner. By accessing this website, www.trilegal.com, you acknowledge that:

  • You are seeking information about Trilegal of your own accord and there has been no form of solicitation, advertisement or inducement by Trilegal or its members.
  • This website should not be construed as providing legal advice for any purpose.
  • All information, content, and materials available on this website are for general informational purposes only.
  • Any information obtained or material downloaded from this website is completely at the user’s volition, and any transmission, receipt or use of this website is not intended to, and will not, create any lawyer-client relationship.
  • Information on this website may not constitute the most up-to-date legal or other information. Trilegal is not liable for the consequences of any action taken by any person based on any material or information available on this website, or for any inaccuracy in or exclusion of any information or interpretation thereof.
  • Readers of this website or recipients of content or information available on this website should not act based on any or all such content or information, and should always seek advice of competent legal counsel licensed to practice in the appropriate jurisdiction.
  • Third party links contained on this website re-directing users to such third-party websites should neither be construed as legal reference / legal advice, nor considered as referrals to, endorsements of, or affiliations with, any such third party website operators.
  • The communication platform provided on this website should not be used for exchange of any confidential, business or politically sensitive information.
  • The contents of this website are the intellectual property of Trilegal.

We prioritize your privacy. Before proceeding, we encourage you to read our privacy policy, which outlines the below, and terms of use to understand how we handle your data:

  • The types of information we collect and why we collect them.
  • How we use your information to provide a personalized experience.
  • The measures we take to ensure the security of your data.
  • Your rights and choices in managing your personal information.
  • How we may share information with trusted partners for specific purpose.

For more information, please read our terms of use and our privacy policy.

Up arrow